EFFECTIVE USE OF MONOCLONAL ANTIBODIES AGAINST TNF — ADALIMUMAB — AS A SWITCHOVER DRUG IN A PATIENT WITH JUVENILE IDIOPATHIC POLYARTHRITIS AND UVEITIS
https://doi.org/10.15690/pf.v11i6.1218
Abstract
The article presents a case of severe juvenile idiopathic arthritis associated uveitis in a patient who contracted the disease at the age of 10 year. Uveitis developed 9 months after manifestation of the articular syndrome in the event of etanercept therapy. Switch to adalimumab induced remission of the articular syndrome and uveitis. By the 8th week of treatment, an inactive disease stage (6 months) was diagnosed in a child.
About the Authors
S. A. Ushakova
Tyumen State Medical Academy, Tyumen, Russian Federation
Russian Federation
Russian Federation
N. L. Ashcheulova
Regional Clinical Hospital, Salekhard, Russian Federation
Russian Federation
Russian Federation
L. N. Koneva
Regional Clinical Hospital № 1, Tyumen, Russian Federation
Russian Federation
Russian Federation
O. Yu. Khalidullina
Tyumen State Medical Academy, Tyumen, Russian Federation
Regional Clinical Hospital № 1, Tyumen, Russian Federation
Russian Federation
Russian Federation
O. V. Pavlova
Tyumen State Medical Academy, Tyumen, Russian Federation
Regional Clinical Hospital № 1, Tyumen, Russian Federation
Russian Federation
Russian Federation
V. S. Rezenova
Regional Clinical Hospital № 1, Tyumen, Russian Federation
Russian Federation
Russian Federation
V. N. Luk'yanova
Regional Clinical Hospital № 1, Tyumen, Russian Federation
Russian Federation
Russian Federation
E. E. Fedorova
Regional Clinical Hospital № 1, Tyumen, Russian Federation
Russian Federation
Russian Federation
M. V. Pshenichkova
Regional Clinical Hospital № 1, Tyumen, Russian Federation
Russian Federation
Russian Federation
References
1. Baranov A.A., Alexeeva E.I., Bzarova T.M., Valieva S.I., Denisova R.V., Isaeva K.B., Karagulyan N.A., Litvitskii P.F., Mitenko E.V., Sleptsova T.V., Fetisova A.N., Chistyakova E.G., Taibulatov N.I., Morev S.Yu. Minutes of the management of patients with juvenile arthritis. Voprosy sovremennoi pediatrii = Current Pediatrics. 2013; 12 (1): 37–56.
2. Alexeeva E.I., Litvitskii P.F. Yuvenil'nyi revmatoidnyi artrit: etiologiya, patogenez, klinika, algoritmy diagnostiki i lecheniya: ruk. dlya vrachei, prepodavatelei, nauch. sotr. Pod obshch. red. A.A. Baranova [Juvenile Rheumatoid Arthritis: Etiology, Pathogenesis, Clinical Features, Diagnosis and Treatment Algorithms: Guideline for Doctors, Teachers, Researchers et al. Edited by A.A. Baranov]. Moscow,VEDI, 2007. 368 p.
3. Rukovodstvo po detskoi revmatologii. Pod red. N.A. Geppe, N.S. Podchernyaevoi, G.A. Lyskinoi [Guidelines for Pediatric Rheumatologists. Edited by N.A. Geppe, N.S. Podchernyaeva, G.A. Lyskina]. Moscow, GEOTAR-Media. 2011.720 p.
4. Malievskii V.A. Quality of life in children with juvenile idiopathic arthritis. Voprosy sovremennoi pediatrii. Prilozhenie «Revmaticheskie bolezni» = Current Pediatrics. Appendix "Rheumatic Diseases". 2006; 5 (2): 5–11.
5. Nikishina I.P., Kuz'mina N.N. Modern pharmacotherapy of juvenile arthritis. Vestnik Rossiiskoi akademii meditsinskikh nauk = Annals of the Russian academy of medical sciences. 2008; 6: 41–48.
6. Vitale A.T., Graham E., de Boer J.H. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm. 2013 Dec; 21 (6): 478–85. Doi: 10.3109/09273948.2013: 815785.
7. Heiligenhaus A., Heinz C., Edelsten C., Kotaniemi K., Minden K. Review for disease of the year: epidemiology of juvenile idiopathic arthritis and its associated uveitis: the probable risk factors. Ocul Immunol Inflamm. 2013; 21 (3): 180–191. Doi: 10.3109/09273948.2013.791701.
8. Salugina S.O., Fedorov E.S. Modern approaches to the treatment of juvenile arthritis. Farmateka = Pharmateca. 2013; 20: 42–48.
9. Baranov A.A., Alekseeva E.I., Valieva S.I., Bzarova T.M., Mitenko E.V., Denisova R.V., Fetisova A.N., Sleptsova T.V., Isaeva K.B., Chistyakova E.G., Taibulatov N.I., Chomakhidze A.M. Therapy using genetically engineered biological agents: efficacy and safety switch. Voprosy sovremennoi pediatrii = Current Pediatrics. 2014; 13 (1): 33–50.
10. Horneff G. Update on biologicals for treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther. 2013 Mar; 13 (3): 361–76. Doi: 10.1517/14712598.2013.735657.
11. Stoll M.L., Cron R.Q. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J. 2014 Apr 23; 12: 13. Doi: 10.1186/1546-0096-12-13.
12. Neroev V.V., Katargina L.A., Denisova E.V. Results and prospects of genetically engineered biological agents in the treatment of endogenous uveitis in children. Rossiiskii oftal'mologicheskii zhurnal = Russian Ophthalmological Journal. 2012; 2: 39–44.
13. Heiligenhaus A., Michels H., Schumacher C. et al. Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatology International. 2012; 32 (5): 1121–1133.
14. Qian Y., Acharya N.R. Juvenile idiopathic arthritis-associated uveitis. Curr Opin Ophthalmol. 2010. Nov; 21 (6): 468–72. Doi: 10.1097/ICU.0b013e32833eab83.
15. García-De-Vicuña C., Díaz-Llopis M., Salom D., Bou R., Díaz-Cascajosa J., Cordero-Coma M., Ortega G., Ortego-Centeno N., Suarez-De-Figueroa M., Cruz-Martínez J., Fonollosa A., Blanco R., García-Aparicio Á.M., Benítez-Del-Castillo J.M., Antón J. Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis. Mediators Inflamm. 2013. Published online Dec 30, 2013. Doi: 10.1155/2013/560632.
16. Simonini G., Taddio A., Cattalini M. et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care and Research. 2011; 63 (4): 612–618.
17. Kotaniemi K., Säilä H., Kautiainen H. Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis. Clinical Ophthalmology. 2011; 5 (1): 1425–1429.
18. Alexeeva E.I., Lisitsin A.O., Karagulyan N.A., Lomakina O.L., Valieva S.I., Bzarova T.M., Denisova R.V., Gudkova E.Yu., Chomakhidze A.M., Isaeva K.B. Adalimumab: new treatment of rheumatic diseases. Voprosy sovremennoi pediatrii = Current Pediatrics. 2009; 8 (3): 20–26.
19. Alexeeva E.I., Mitenko E.V., Valieva S.I., Bzarova T.M., Denisova T.V., Isaeva K.B., Sleptsova T.V., Chomakhidze A.M. Efficacy and safety of adalimumab in children with juvenile idiopathic arthritis and uveitis. Voprosy sovremennoi pediatrii = Current Pediatrics. 2012; 11 (1): 111–118.
20. Zholobova E.S., Galstyan L.A., Nikolaeva M.N., Loskutova O.Yu. The effectiveness of adalimumab in the treatment of juvenile idiopathic arthritis with uveitis. Pediatriya = Pediatrics. 2014; 5: 66–71.
21. Pilly B., Heath G., Tschuor P., Lightman S., Gale R.P. Overview and recent developments in the medical management of paediatric uveitis. Expert Opin Pharmacother. 2013 Sep; 14 (13): 1787–95. Doi: 10.1517/14656566.2013.816677.
22. Luchikhina E.L., Karateev D.E., Nasonov E.L. The first experience with adalimumab in Russia: preliminary results of a 24-week open-label study. Nauchno-prakticheskaya revmatologiya = Scientific and Practical rheumatology. 2008; 5: 59–63.
23. Nikishina I.P., Arsen'eva S.V., Alekseev D.L., Smirnov A.V. Pauci-articulary juvenile arthritis-associated uveitis ANF: a clinical observation in the case of a family of mother and daughter with the outcome in ankylosing spondylitis in the mother. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2014; 11 (1): 44–50.
24. Alekseeva E.I., Isaeva K.B., Denisova R.V., Sleptsova T.V., Valieva S.I., Bzarova T.M., Mitenko E.V., Chomakhidze A.M. Experience of using monoclonal antibodies to TNF α - adalimumab - a child with juvenile idiopathic arthritis. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2013; 10 (4): 149–153.
25. Malievskii V.A., Nizhevich A.A., Pervushina E.P., Sapronova L.Yu. Experience in the use of adalimumab in patients with juvenile arthritis with uveitis in the background of Crohn's disease. Voprosy sovremennoi pediatrii = Current Pediatrics. 2013; 12 (4): 181–184.
26. Neroev V.V., Katargina L.A., Denisova E.V., Starikova A.V., Lyubimova N.V. The effectiveness of genetically engineered biological agents in the treatment of uveitis associated with rheumatic diseases in children. Nauchno-prakticheskaya revmatologiya = Scientific and Practical rheumatology. 2012; 53 (4): 91–95.
27. Ramanan A.V., Dick A.D., Benton D., Compeyrot-Lacassagne S., Dawoud D., Hardwick B., Hickey H., Hughes D., Jones A., Woo P., Edelsten C., Beresford M.W. A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial). Trials. 2014 Jan 9; 15: 14. Doi: 10.1186/1745-6215-15-14.
Review
For citations:
Ushakova S.A., Ashcheulova N.L., Koneva L.N., Khalidullina O.Yu., Pavlova O.V., Rezenova V.S., Luk'yanova V.N., Fedorova E.E., Pshenichkova M.V. EFFECTIVE USE OF MONOCLONAL ANTIBODIES AGAINST TNF — ADALIMUMAB — AS A SWITCHOVER DRUG IN A PATIENT WITH JUVENILE IDIOPATHIC POLYARTHRITIS AND UVEITIS. Pediatric pharmacology. 2014;11(6):66-72. (In Russ.) https://doi.org/10.15690/pf.v11i6.1218
Views:
641
Email this article 